Skip to content

Clinical trials

Phase 2 Genetic Diseases, Inborn trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Genetic Diseases, Inborn Phase: Phase 2 Country / region: France Clear all

14 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20102
20113
20181
20192
20201
20212
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Terminated3
Enrolling by invitation2
Recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals3
QED Therapeutics, a BridgeBio company3
Alnylam Pharmaceuticals1
Assistance Publique - Hôpitaux de Paris1
CSL Behring1
GenSight Biologics1
Intergroupe Francophone du Myelome1
Laboratoires Thea1
Novo Nordisk A/S1
Pharnext S.C.A.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Genetic Diseases, Inborn14
Bone Diseases3
Fragile X Syndrome3
Mucopolysaccharidosis IV3
Musculoskeletal Diseases3
Osteochondrodysplasias3
Achondroplasia2
Dwarfism2
Eye Diseases2
Hyperoxaluria, Primary2

Trials

Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.